52
Special Populations
6.5. Women, Including Pregnancy and Postmenopausal
Hormone Therapy
COR LOE
Recommendations
Pregnancy
1 C-LD 1. Women with CCD who are contemplating pregnancy or who are
pregnant should be risk-stratified and counseled regarding risks of
adverse maternal, obstetric, and fetal outcomes.
1 C-LD 2. Women with CCD who are contemplating pregnancy or who
are pregnant should receive care from a multidisciplinary
cardio-obstetric care team beginning before conception and
continuing throughout pregnancy, delivery, and postpartum
to improve maternal and fetal outcomes.
2b C-LD 3. In women with CCD, continuation of statin use during
pregnancy may be considered.
3: Harm C-LD 4. Women with CCD who are contemplating pregnancy or who
are pregnant should not use ACE inhibitors, ARBs, direct
renin inhibitors, angiotensin receptor-neprilysin inhibitors,
or aldosterone antagonists during pregnancy to prevent harm
to the fetus.
Postmenopausal Hormone erapy
3: Harm A 5. Women with CCD should not receive systemic
postmenopausal hormone therapy because of a lack of benefit
on MACE and mortality, and an increased risk of venous
thromboembolism.
